Xiang-yang D. Ye

AstraZeneca R&D
Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 65 publications

An updated patent review of STAT6 inhibitors and modulators (2020 - present).

An updated patent review of STAT6 inhibitors and modulators (2020 - present).

Journal: Expert opinion on therapeutic patents

Published: August 05, 2026

Bioorthogonal chemistry-driven multi-enzyme strategy for efficient terpenoid biosynthesis.

Bioorthogonal chemistry-driven multi-enzyme strategy for efficient terpenoid biosynthesis.

Journal: Bioresource technology

Published: April 27, 2026

Bioorthogonal chemistry-driven multi-enzyme strategy for efficient terpenoid biosynthesis.

Bioorthogonal chemistry-driven multi-enzyme strategy for efficient terpenoid biosynthesis.

Journal: Bioresource technology

Published: April 27, 2026

Correction to "Design and Synthesis of Pyrrolo[3,4-d]pyrimidine-Based ATR Degraders for Effective Treatment of Colorectal Cancer in Mouse Model".

Correction to "Design and Synthesis of Pyrrolo[3,4-d]pyrimidine-Based ATR Degraders for Effective Treatment of Colorectal Cancer in Mouse Model".

Journal: Journal of medicinal chemistry

Published: March 28, 2026

Design and Synthesis of Pyrrolo[3,4-d]pyrimidine-Based ATR Degraders for Effective Treatment of Colorectal Cancer in Mouse Model.

Design and Synthesis of Pyrrolo[3,4-d]pyrimidine-Based ATR Degraders for Effective Treatment of Colorectal Cancer in Mouse Model.

Journal: Journal of medicinal chemistry

Published: March 06, 2026

Design, synthesis and anti-breast cancer activity evaluation of 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine-based PARP1/ATR dual inhibitors.

Design, synthesis and anti-breast cancer activity evaluation of 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine-based PARP1/ATR dual inhibitors.

Journal: Journal of enzyme inhibition and medicinal chemistry

Published: February 16, 2026

Anticancer natural products derived from fungi: A review of promising lead compounds.

Anticancer natural products derived from fungi: A review of promising lead compounds.

Journal: European journal of medicinal chemistry

Published: December 24, 2025

Advances in TCDD-inducible poly(ADP-ribose) polymerase (TiPARP/PARP7) research: From molecular mechanisms to therapeutic applications.

Advances in TCDD-inducible poly(ADP-ribose) polymerase (TiPARP/PARP7) research: From molecular mechanisms to therapeutic applications.

Journal: Biochemical pharmacology

Published: August 28, 2025

Combining PD-L1 blockade with a second-generation HSP110 inhibitor enhances antitumor immunity in colorectal cancer.

Combining PD-L1 blockade with a second-generation HSP110 inhibitor enhances antitumor immunity in colorectal cancer.

Journal: Cell death & disease

Published: June 02, 2025

Poly(ADP-ribose) polymerase-1 (PARP1)-based dual inhibitors targeting cancer synthetic lethality (2022-present): advances and perspectives.

Poly(ADP-ribose) polymerase-1 (PARP1)-based dual inhibitors targeting cancer synthetic lethality (2022-present): advances and perspectives.

Journal: European journal of medicinal chemistry

Published: May 20, 2025

Design, synthesis, and biological evaluation of aminopyrazine-based ATR/HDACs dual inhibitors.

Design, synthesis, and biological evaluation of aminopyrazine-based ATR/HDACs dual inhibitors.

Journal: Molecular diversity

Published: April 14, 2025

A novel PARP-ATR dual inhibitor exhibits anti-triple-negative breast cancer activity by inducing excessive DNA damage in the mitotic phase.

A novel PARP-ATR dual inhibitor exhibits anti-triple-negative breast cancer activity by inducing excessive DNA damage in the mitotic phase.

Journal: Biochemical pharmacology

Published: March 25, 2025

Showing 1-12 of 65

Last Updated: 09/26/2026